Chemotherapy in hormone refractory prostate cancer: Where do we stand?

European Urology

Volumn 46, Issue 6, 2004, Pages 709-711

  Clarke, Noel W ^a,b   Wylie, James P ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; ENDOTHELIN RECEPTOR ANTAGONIST; ESTRAMUSTINE; GEFITINIB; MITOXANTRONE; NAVELBINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; STEROID; STRONTIUM; TAXANE DERIVATIVE; TRASTUZUMAB; ZOLEDRONIC ACID;

BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG FATALITY; EDITORIAL; GASTROINTESTINAL TOXICITY; HUMAN; LYMPHOMA; NEUROTOXICITY; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 8544284123     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.08.023     Document Type: Editorial

References (18)

1. A. Yagoda, and D. Petrylak Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer Cancer 71 1993 1098 1109
2. R. Casciano, and D. Petrylak Systematic review of chemotherapy efficacy from controlled trials in hormone refractory prostate cancer patients Proc Am Soc Clin Oncol 20 2001 2428
3. I.F. Tannock, D. Osaba, and M.R. Stockler Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomised trial with palliative end points J Clin Oncol 14 1996 1764 1765
4. P.W. Kantoff, S. Halabi, and M. Conaway Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukaemia group B 9182 study J Clin Oncol 17 1999 2506 2513
5. Eisenberger MA, De Wit R, Berry W, et al, A multi-centre phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone refractory prostate cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2004 (145) [Abstract 4].
6. Petrylak DP, Tangen C, Hussain M, et al. SWOG 99-16: randomised phase III trial of docetaxel (D)/estramustine (E) vs. mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2004 (145) [Abstract 3].
7. British Association of Urological Surgeons Cancer Registry, Minimum Data Set 2001.
8. Clarke NW Management of hormone escaped prostate cancer BJU Int 92 2003 860 868
9. ®, Available at: http://www.emims.net.
10. 89radioactive strontium for patients with bone metastases from prostate cancer BJU Int 86 2000 929 934
11. F. Saad, D.M. Gleason, and R. Murray A randomised placebo-controlled trial of zoledronic acid in patients with hormone refractory prostate cancer J Natl Canc Inst 94 2002 1458
12. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumour progression in men with hormone refractory prostate cancer: a randomised, phase 2, placebo controlled trial. J Clin Oncol 2003:15;21(4):679-89.
13. Carducci M, Nelson JB, Saad F, et al. Effects of Atrasentan on disease progression and biological markers in men with metastatic hormone refractory prostate cancer: Phase 3 study. ASCO Annual Meeting Proceedings. J Clin Oncol 2004 (145) [Abstract 4508].
14. G. Di Lorenzo, C. Pizza, and R. Autorino Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer Eur Urol 46 6 2004 712 716
15. R.L. Jones, and I.E. Smith Efficacy and safety of trastuzamab Expert Op Drug Safety 3 4 2004 317 327
16. J.G. Paez, P.A. Janne, and J.C. Lee EGFR Mutations in lung cancer: correlation with clinical response to Gefitinib therapy Science 304 2004 1497 1500
17. T.J. Lynch, B.W. Bell, and R. Sordelloa Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to Gifitinib NEJM 350 21 2004 2129 2139
18. B. Coiffier New treatment strategies in lymphomas: aggressive lymphoma Ann Hematol 83 Suppl 1 2004 71 74